UK Appeals Court Overturns Tribunal Decision in Long-Running Pfizer-Flynn Antitrust Case

In a judgment issued Friday, the appellate court concluded that the tribunal exceeded its powers when it replaced findings made by the Competition and Markets Authority (CMA) after setting aside portions of the regulator’s case. According to Law360, the court determined that the tribunal should not have issued its own infringement ruling after identifying flaws in the CMA’s analysis.

The case stems from allegations that Pfizer and Flynn Pharma abused dominant positions in the market for phenytoin sodium capsules, an anti-epilepsy treatment. UK competition authorities first investigated the companies after substantial increases in the drug’s price following changes to its regulatory status.

The CMA originally imposed significant financial penalties against the companies in 2016, alleging that the prices charged for the medicine were excessive and unfair. The regulator argued that the conduct violated competition rules prohibiting the abuse of a dominant market position.

The dispute has generated a series of appeals and reviews over nearly a decade, becoming one of the most closely watched excessive-pricing cases in UK competition law. Earlier court rulings had sent aspects of the matter back to the CMA for reconsideration, while also addressing how regulators should evaluate whether prices are unlawfully excessive.

Related: Pfizer Files Second Lawsuit Over Novo Nordisk’s Bid for Metsera

At the center of the latest appeal was a question of institutional authority rather than the underlying economics of the drug market. The Court of Appeal examined whether the Competition Appeal Tribunal could effectively substitute its own findings after rejecting portions of the CMA’s decision.

The appellate court concluded that the tribunal’s role was limited to reviewing the regulator’s decision and determining whether it should stand. According to Law360, the judges found that the tribunal was wrong to remake the infringement decision itself after setting aside the CMA’s conclusions.

The ruling is significant for antitrust enforcement because it clarifies the respective responsibilities of the CMA and the specialist tribunal that reviews competition cases. The decision addresses how far appellate bodies can go when reviewing abuse-of-dominance investigations, particularly in complex excessive-pricing cases involving pharmaceutical products.

The Pfizer-Flynn litigation has been closely followed by competition lawyers and regulators because it has helped shape the legal framework governing excessive-pricing allegations. The case has also examined how competition authorities should assess economic value, market comparisons and fairness when determining whether a dominant company has breached antitrust rules.

Source: Law360